Mortality is high among patients heart failure (HF) who are receiving treatment, and therefore identifying new pathways rooted in preclinical cardiac remodeling phenotypes may afford novel biomarkers and therapeutic avenues. Circulating extracellular RNAs (ex-RNAs) are an emerging class of biomarkers with target-organ epigenetic effects relevant to myocardial biology, although large human investigations remain limited.
D espite successful therapies for heart failure (HF) that target remodeling pathways, the mortality rate of patients receiving treatment remains high. Efforts to identify alternative mechanisms that contribute to myocardial remodeling at an earlier stage in disease may improve screening and open new therapeutic avenues for HF. Extracellular ribonucleic acids (termed ex-RNAs) are circulating, stable, noncoding RNA molecules that can serve as biomarkers of cardiovascular diseases and, importantly, may also exert epigenetic control of overexpression of a wide array of genes whose products are implicated in myocardial remodeling and HF. The ability to identify a role for ex-RNAs in human HF has been limited to studies of patients with severe or established HF and small cohorts with limited phenotypic characterization without a prognostic time horizon. Here, we address this important gap by identifying ex-RNAs associated with echocardiographic left ventricular (LV) remodeling phenotypes and incident HF during long-term follow-up in the Framingham Heart Study (FHS).
The FHS is a community-based observational cohort study of cardiovascular disease in Framingham, Massachusetts, with serial examinations of participants every 4 to 8 years. The study sample for this investigation consists of individuals in the FHS Offspring cohort who had both detailed echocardiography and plasma collected at their eighth examination (in 2005 to 2008). Written informed consent was obtained from all study participants, with institutional review board approval received at Boston University and the University of Massachusetts.
The techniques used for plasma collection and ex-RNA quantification in FHS have been previously published. 1 We included ex-RNAs (microRNAs, or miRNAs; small nucleolar RNAs, or snoRNAs; and piwi-interacting RNAs, or piRNAs) expressed within the linear range of a Fluidigm Biomark System thermocycler (Fluidigm; 6 to 23 polymerase chain reaction cycles) in at least 100 FHS participants, yielding 301 miRNAs, 59 piRNAs, and 38 snoRNAs (eTable 1 in the Supplement). We performed echocardiography as previously published 2 
to measure LV mass (LVM), LV size (by LV enddiastolic volume [LVEDV]), LV function (by LV ejection fraction [LVEF] or fractional shortening [FS])
, and left atrial dimension (LAD). We used the Devereux method for enddiastolic LVM, 3 and the Teichholz method for LV volume, 4 normalized to height to the 2.7th power. The overall strategy was to measure associations between ex-RNAs and echocardiographic indices of cardiac remodeling as a screening test for those candidate ex-RNAs potentially relevant to preclinical HF phenotypes. Subsequently, we tested the association of these candidate ex-RNAs with incident all-cause HF.
Echocardiographic indices were log-transformed based on visual assessment of distributions to approximate a normal distribution prior to regression. We constructed ageadjusted, sex-adjusted linear regression models to associate each echocardiographic index with each ex-RNA. Given multiple models (1 model per each ex-RNA), we established a 5% false discovery rate (via the Benjamini-Hochberg false discovery rate approach) to screen associations. The ex-RNAs associated with LVM and 1 additional echocardiographic phenotype (LVEDV, LVEF, FS, or LAD) were moved into models for incident HF (which were diagnosed as previously published).
5,6
Based on previous large consortium efforts in HF prediction, 7 we used Cox proportional hazards regression for incident HF for each candidate ex-RNA, first in a model adjusted for age, sex, prevalent myocardial infarction (MI), and incident MI (modeled as a time-dependent covariate) (model 1); and then in a model further adjusted for diabetes, body mass index (calculated as weight in kilograms divided by height in meters squared), systolic blood pressure, lifetime use of antihypertensive medications, and current smoking (model 2). Survival plots were generated using the %survplot macro in SAS (Ryan Lennon). Finally, we identified networks of genes and pathways regulated by candidate ex-RNAs using previously published techniques (including open-source tools such as Enrichr, Cytoscape, and WikiPathways, among others, as described in eMethods in the Supplement).
8 All statistics were performed with SAS software version 9.3 (SAS Institute) with a 2-tailed P value less than .05 considered statistically significant. Data analysis was completed from December 2016 to June 2018.
Results
The baseline clinical and echocardiographic characteristics of our study sample are shown in the We constructed age-adjusted and sex-adjusted linear regression models to identify associations between ex-RNAs and each echocardiographic parameter (eTable 2 in the Supplement). We found 29 ex-RNAs associated with LVM (with associations ranging from β = −0.025; P =4 . 5 2×1 0 −4 for from β = −0.015; P =5.43×10 −4 for miR-33a-3p to β = −0.006; P =2.60×10 −4 for piRNA-54042), and 7 associated with LVEDV (at a false detection rate threshold of 0.051; associations ranged from β = −0.015; P =4. 39×10 −4 for miR-20b-5p to β = −0.011; P =7 . 90×10 −4 for miR-26b-5p and β = −0.011; P =8. 97×10 −4 for miR-106b-5p). Twelve ex-RNAs were associated with LVM and at least 1 other echocardiographic phenotype (with LAD: miR-126-5p, piRNA-54043, miR-26a-5p, piRNA-54042, miR-23a-3p, and miR-126-3p; with LVEDV: mIR-20a-5p, miR-93-5p, miR-20b-5p, miR-106b-5p, and miR-17-5p; with both LAD and LVEDV: miR-26b-5p). Negative β-coefficients signify that increased plasma abundance of each ex-RNA was associated with a decrease in LV mass.
Of the initial 2763 participants in the study cohort, 72 (2.6%) had a history of HF diagnosed before the eighth examination cycle and were excluded from the analysis, leaving 2691 individuals (97.4%). Of these 2691 individuals, HF status was adjudicated on 2681 study participants (99.6%), with 116 cases diagnosed at a median follow-up of 7.7 years (interquartile range, 6.6-8.6 years). Notably, 9 of these cases (7.8%) had a previous diagnosis of myocardial infarction; of the 107 individuals without a prevalent MI before the eighth examination, 17 participants experienced an incident MI before the time of HF diagnosis in follow-up (15.9%). The number of FHS participants included in each survival analysis varied based on overlap between participants with HF status available, RNAs quantified, and adjustments (eTable 3 in the Supplement). The results of Cox proportional hazards regression for the association of the 12 candidate ex-RNAs with incident HF are shown in eTable 3 in the Supplement. Lower plasma abundance of miR-106b-5p, miR-17-5p, and miR-20a-5p were associated with a nearly 15% higher hazard of incident all-cause HF after adjustment in model 1 (miR-20a-5p: HR, 0. These 3 miRNAs (miR-20a, miR-106b, and miR-17) have a similar sequence and are members of a tight cluster, regulating 883 messenger RNAs in common among all 3 miRNAs, plus another 54 messenger RNAs targeted by 2 of the 3 miRNAs. We found significant homology between these 3 miRNAs in seed sequence. Figure 2 shows the results of an enrichment analysis performed using Enrichr 9 with the 937 genes (total) targeted by at least 2 of miR-20a-5p, miR-17-5p, and miR-106b-5p. 
Discussion
We found 12 circulating ex-RNAs in plasma associated with cardiac remodeling, 3 of which were associated with incident HF over a period longer than 7 years in FHS. Three noncoding ex-RNAs associated with cardiac structure and HF (miR-17-5p, miR-20a-5p, and miR-106b-5p) exhibited significant sequence homology and targeted a set of genes involved in processes potentially relevant to cardiomyocyte biology in HF. Each specified a disease association with hypertension, which is a leading cause of HF. Previous animal models of HF support a functional role for the miR-17-92 cluster, 13 miR-20a, 14 and miR-106b.
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Limitations
These findings are exploratory and limited by lack of external validation, a more precise characterization of subtype of HF (as preserved vs reduced LVEF), and additional biomarker measurements. We focused on echocardiographic endophenotypes that reflect early markers of LV remodeling relevant to HF (eg, LV mass), given their universal acquisition and load-independence; further investigation of more specific serologic or imaging-based markers of earlier alterations in the course of HF (eg, fibrosis) are warranted. Technically, methods for RNA isolation and quantification are 
Research Brief Report
Associations of Circulating Extracellular RNAs With Myocardial Remodeling and Heart Failure variable across different laboratories, and the sequence specificity of our polymerase chain reaction probes is an important limitation: the miR-106b-5p and miR-20a-5p primers may uniquely quantify these miRNAs, while the miR-17-5p primer detected both miR-17-5p and miR-106a-5p. We did not observe associations between the 3 miRNAs and HF with preserved or reduced LVEF individually, owing to a lack of power for each disease subtype; further studies in these specific, pathophenotypically distinct patient subsets are warranted. Finally, contemporaneous high-sensitivity measurements of troponin or natriuretic peptide were not available at the time of ex-RNA quantification.
Conclusions
In conclusion, we found several noncoding ex-RNAs associated with LV phenotypes and incident HF in a community-based prevention cohort. To our knowledge, no large primary prevention cohorts currently include sufficient follow-up, measurements of noncoding RNAs, echocardiographic phenotypes, and HF events for validation. Further investigations into the relevance of circulating ex-RNAs are warranted to improve detection and therapy in HF. Funding/Support: This research was conducted using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute and Boston University School of Medicine (grants HHSN268201500001I and N01-HC 25195, Dr Vasan) and was funded by a Career Development Award from the National Institutes of Health (grant K23-HL127099, Dr Shah), National Institutes of Health Common Fund Awards (grants U01-HL126495 and UH3-TR000921, Dr Freedman), a grant from the National Heart, Lung, and Blood Institute Division of Intramural Research (Dr Levy), and further grants from the National Institutes of Health (grants R01-HL122987, R01-HL135886, and UH2-TR000901, Drs Rosenzweig and Liu; grants UH3-TR000901 and R01-HL122547, Dr Das), as well as funding from the American Heart Association (grant SFRN31740000, Drs Rosenzweig, Das, and Freedman).
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eMethods. Pathway analysis
Gene targets of candidate exRNAs were extracted from experimentally validated interactions in miRTarBase version 6.1 using Target Interaction Finder.1 The output included an xGMML network file that was imported into Cytoscape for subnetwork analysis and data visualization.2 Sub-networks were generated using topological filters to exclude targets of just one exRNA in order to focus on targets with a greater number of candidate exRNA associations and more supporting evidence. Functional characterization of targeted genes was performed using the bioinformatics tool, Enrichr,3 which provided significance scores for enriched processes and pathways from Gene Ontology and WikiPathways4 and disease terms from OMIM in a tabular format. eTable 1. List of circulating extracellular RNAs included in the study. N specifies number of participants in whom ex-RNA quantification was possible. Mean specifies mean PCR cycle value. SD specifies standard deviation. American Medical Association All rights reserved eTable 2. Age-and sex-adjusted linear models for the association between cardiac structural parameters and extracellular RNAs. Each beta coefficient is expressed as the change in log-echo parameter for a two-fold increase in circulating RNA level. All ex-RNAs are significant at a prespecified FDR rate of 0.05; LVEDV associations had an FDR level of 0.051 and were included here. Ex-RNAs in red are associated with at least 2 phenotypes. Figure 2A was the TGF-beta Signaling Pathway from WikiPathways (https://www.wikipathways.org/index.php/Pathway:WP560). The specific miRNA targets enriched in the pathway are indicated in blue. A red border indicates genes in the pathway that interact the miRNA targets enriched in the OMIM term for hypertension (also from Enrichr results) based on GeneMANIA, restricted to default sources of physical, pathway, co-expression and genetic interaction types (i.e., excluding predicted, colocation and others). The pathway and data visualization was performed using Cytoscape. 
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